Why the study?
Does sulfinpyrazone improve haemostatic parameters in young male patients 6 months post-myocardial infarction?
Does sulfinpyrazone improve haemostatic parameters in young male patients 6 months post-myocardial infarction?
Answers are grounded in this paper and cite their sources.
Sulfinpyrazone normalizes platelet production time and reduces factor VIII related antigen in young male patients 6 months after myocardial infarction.
In the Anturane Reinfarction Italian Study the trend of some specific and quantitative haemostatic parameters is being investigated in different series of patients balanced for sulfinpyrazone and placebo. In a series of young male patients who had had myocardial infarction 6 months previously, it has been shown that the placebo treatment subsample presented shortened platelet production time (PPT), increased levels of plasma beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), and increased factor VIII related antigen (VIII:RAg) compared with a matched control group. A close correlation between plasma concentration of VIII:RAg and PPT was evidenced in the same treatment subsample. The sulfinpyrazone treatment subsample presented normalized PPT accompanied by reduction of VIII:RAg but not of beta-TG or PF4 levels.
No takes yet. Share an insight, caveat, or question.
Cortellaro et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: